Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 5/2016

Open Access 01-09-2016 | Original Article

The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean

Authors: Anbok Lee, Juhyun Woo, Heejung Park, Sun Hee Sung, Ju-Young Seoh, Woosung Lim, Byung-In Moon

Published in: Breast Cancer | Issue 5/2016

Login to get access

Abstract

Background

The human Y-box-binding protein 1 (YB-1) is a member of the DNA/RNA-binding family of proteins that regulates transcription and translation of genes. Previous studies suggest that YB-1 may have an oncogenic role in various cancers. In this study, we evaluate the prognostic value of cytoplasmic YB-1 with respect to breast cancer.

Methods

Immunohistochemical staining study was performed with YB-1 using tissue block from 233 patients with invasive ductal carcinoma. Patients were divided into two groups according to expression of cytoplasmic YB-1 in tumor cell (high versus low). The relationship between the expression of YB-1, clinicopathological characteristics and breast cancer prognosis was analyzed.

Results

Hormone receptor negativity, worse histologic and nuclear grade, high tumor stage, lymphovascular invasion and high Ki67 (≥14 %) were related with the increased expression of cytoplasmic YB-1 in tumor cell (p < 0.05). Although there was no significant difference in relapse-free survival (RFS) between the two groups (p = 0.412), difference in overall survival (OS) was statistically significant (p = 0.035). In multivariate analysis for OS, YB-1 was an independent prognostic factor (p = 0.043).

Conclusion

This suggests that the increased expression of cytoplasmic YB-1 in tumor cells can be regarded as an independent prognostic factor for breast cancer, related to poor prognostics. Expression of cytoplasmic YB-1 in cancer cell could be used as an independent prognostic marker for predicting OS in breast cancer.
Literature
1.
Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat. 2012;134:363–70.CrossRefPubMed
2.
Di CS, Baselga J. Management of breast cancer with targeted agents: importance of heterogenicity. Nat Rev Clin Oncol. 2010;7:139–47.CrossRef
3.
Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochem (Mosc). 2011;76:1402–33.CrossRef
4.
Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA. 1988;85:7322–6.CrossRefPubMedPubMedCentral
5.
Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays. 2003;25:691–8.CrossRefPubMed
6.
Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151–5.PubMed
7.
Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer (Phila.). 1999;85:2450–4.CrossRef
8.
Xie W, Yang J, Cao Y, Peng C, Ning H, Zhang F, et al. Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer. Tumour Biol. 2012;33:63–71.CrossRefPubMed
9.
Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol. 2003;199:251–8.CrossRefPubMed
10.
Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3:447–50.CrossRefPubMed
11.
Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009;9:410.CrossRefPubMedPubMedCentral
12.
Li Y, Wen ZS, Yang HX, Luo RZ, Zhang Y, Zhang MF, et al. High expression of Y-box-binding protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2011;18:3370–6.CrossRefPubMed
13.
Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 2005;11:7354–61.CrossRefPubMed
14.
Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009;22:282–90.CrossRefPubMed
15.
Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008;68:1504–12.CrossRefPubMed
16.
Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66:4872–9.CrossRefPubMed
17.
Lee C, Dhillon J, Wang MY, Gao Y, Hu K, Park E, et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008;68:8661–6.CrossRefPubMed
18.
Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012;133:145–59.CrossRefPubMed
19.
Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M, et al. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol. 2010;37:483–92.PubMed
20.
Gu C, Oyama T, Osaki T, Kohno K, Yasumoto K. Expression of Y-box-binding protein-1 correlates with DNA topoisomerase II alpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res. 2001;21:2357–62.PubMed
21.
Kosnopfel C, Sinnberg T, Schittek B. Y-box binding protein 1–a prognostic marker and target in tumour therapy. Eur J Cell Biol. 2014;93:61–70.CrossRefPubMed
22.
Gopal SK, Greening DW, Mathias RA, Ji H, Rai A, Chen M, et al. YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment. Oncotarget. 2015;6:13718–30.CrossRefPubMedPubMedCentral
23.
Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, et al. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget. 2014;5:2462–74.CrossRefPubMedPubMedCentral
24.
Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15:402–15.CrossRefPubMed
25.
Yi SY, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, et al. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer. 2010;5(10):527.CrossRef
Metadata
Title
The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean
Authors
Anbok Lee
Juhyun Woo
Heejung Park
Sun Hee Sung
Ju-Young Seoh
Woosung Lim
Byung-In Moon
Publication date
01-09-2016
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2016
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0625-8

Other articles of this Issue 5/2016

Breast Cancer 5/2016 Go to the issue

Original Article

Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis

Original Article

The value of primary tumor 18F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis

Original Article

Digital mammography versus digital breast tomosynthesis for detection of breast cancer in the intraoperative specimen during breast-conserving surgery

Original Article

Clinicopathological features of breast angiosarcoma

Original Article

Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer

Original Article

Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits